Pancreatic Adenocarcinoma
Conditions
Keywords
Blood draw, pancreas, Tumorigenic Cells, 11-141
Brief summary
The purpose of this study is to collect blood samples and study cancer cells found in these blood samples from patients with pancreatic cancer. Prior research has discovered that tumor cells can be collected from the blood of patients with pancreatic and other cancers. The physicians have developed techniques for isolating and analyzing cancer cells using a simple blood test. They will study how these cells relate to how chemotherapy works. They hope to use this information to guide choices of treatment for patients in the future.
Interventions
OTHERBlood draw
Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
Sponsors
Adera Labs, LLC
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC. * Patient eligible for chemotherapy treatment. * Prior surgery, chemotherapy and/or radiation therapy for pancreatic adenocarcinoma is permitted. * ECOG performance status 0-2. * A minimum age of 18 years old.
Exclusion criteria
* Known to be HIV positive on antiretroviral therapy * Prior organ allograft * Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| isolating and enriching circulating tumorigenic cells | 1 year | A 10 mL blood sample will be drawn from participants prior to starting chemotherapy treatment. circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients. During the 1 year following enrollment, in the setting of disease progression, a subsequent 10 mL blood sample may be drawn from participants prior to changing chemotherapy treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| successful gene expression profiling | 1 year | of these circulating tumorigenic cells. For each blood sample collected, CTCs will be isolated, expanded, RNA extracted, gene expresion analysis performed and treatment profile sensitivity performed. |
Countries
United States
Outcome results
None listed